The synthetic triterpenoid (CDDO-Im) inhibits STAT3, as well as IL-17, and improves DSS-induced colitis in mice

Inflammopharmacology

Volumn 22, Issue 6, 2014, Pages 341-349

  Fitzpatrick, Leo R ^a,b   Stonesifer, Elizabeth ^b   Small, Jeffrey S ^b   Liby, Karen T ^c  

^a CALIFORNIA NORTHSTATE UNIVERSITY   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Colitis; Interleukin 17; Mice; Splenocytes; Triterpenoid

Indexed keywords

1-(2-CYANO-3,12-DIOXOOLEANA-1,9-DIEN-28-OYL) IMIDAZOLE; DEXTRAN SULFATE; IMIDAZOLE DERIVATIVE; INTERLEUKIN 17; INTERLEUKIN 6; OLEANOLIC ACID; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; TRINITROBENZENESULFONIC ACID;

ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; COLITIS; CYTOLOGY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; IC50; INFLAMMATION; MALE; METABOLISM; MOUSE; PATHOLOGY; SECRETION (PROCESS); SPLEEN; TIME;

ANIMALS; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMIDAZOLES; INFLAMMATION; INHIBITORY CONCENTRATION 50; INTERLEUKIN-17; INTERLEUKIN-6; MALE; MICE; MICE, INBRED BALB C; OLEANOLIC ACID; SPLEEN; STAT3 TRANSCRIPTION FACTOR; TIME FACTORS; TRINITROBENZENESULFONIC ACID;

EID: 84897361986     PISSN: 09254692     EISSN: 15685608     Source Type: Journal    
DOI: 10.1007/s10787-014-0203-2     Document Type: Article

References (26)

1. Auletta JJ, Alabran JL, Kim BG et al (2010) The synthetic triterpenoid, CDDO-Me, modulates the proinflammatory response to in vivo lipopolysaccharide challenge. J Interferon Cytokine Res 30:497–508
2. Camporeale A, Poli V (2012) IL-6, IL-17 and STAT3: a holy trinity in auto-immunity? Front Biosci 17:2306–2326
3. Coccia M, Harrison OJ, Schiering C et al (2011) IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4 + Th17 cells. JEM 209:1595–1609
4. Fitzpatrick LR (2012) Novel pharmacological approaches for inflammatory bowel disease: targeting key intracellular pathways and the IL-23/IL-17 axis. Int J Inflamm 2012:389404. doi:10.1155/2012/389404
5. Fitzpatrick LR (2013) Inhibition of IL-17 as a pharmacological approach for IBD. Int Rev Immunol 32:544–555
6. Fitzpatrick LR, Small J, Hoerr R et al (2008) In vitro and in vivo effects of the probiotic Escherichia coli strain M-17: immunomodulation and attenuation of murine colitis. Br J Nutr 100:530–541
7. Fitzpatrick LR, Demi L, Hofmann C (2010) 4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease. Inflamm Bowel Dis 16:1763–1777
8. Fitzpatrick LR, Small JS, Ammendola A (2011) Inhibition of IL-17 release by the novel anti-inflammatory drug Vidofludimus involves attenuation of STAT3 and NF-kappa B signaling pathways in murine splenocytes and hapten-induced colitis. Gastroenterology 140:S837
9. Fitzpatrick LR, Small JS, Doblhofer R et al (2012) Vidofludimus inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action. JPET 342:850–860
10. Grivennikov SI, Karin M (2010) Dangerous liaisons: STAT3 and NF-kappa B collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 21:11–19
11. He M, Karin M (2011) NF-κB and STAT3—key players in liver inflammation and cancer. Cell Res 21:159–168
12. Hong DS, Kurzrock R, Supko JG et al (2012) A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Canc Ther 18:3396–33406
13. Ito R, Kita M, Shin-Ya M et al (2008) Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice. Biochem Biopys Res Commun 377:12–16
14. Kleinscheck MA, Boniface K, Sadevoka S et al (2009) Circulating and gut resident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med 206:525–534
15. Lee MJ, Lee JK, Cho JW et al (2012) Interleuki-6 induces S100A9 expression in colonic epithelial cells through STAT3 activation in experimental ulcerative colitis. PLoS One 7:1–11
16. Liby K, Voong N, Williams CR et al (2006) The synthetic triterpenoid CDDO-imidazole suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin Cancer Res 12:4288–4293
17. Liby KT, Royce DB, Risingsong R et al (2010) Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. Cancer Prev Res 3:1427–1434
18. Monteleone I, Sarra M, Pallone F et al (2012) Th-17 related cytokines in inflammatory bowel diseases: friend or foes? Curr Mol Med 12:592–597
19. Pareek TK, Belkadi A, Kesapavany S et al (2011) Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis. Sci Rep 1:201. doi:10.1038/srep00201
20. Shen YM, Zhao Y, Zeng Y et al (2012) Inhibition of pim-1 kinase ameliorates dextran sodium sulfate-induced colitis in mice. Dig Dis Sci 57:1822–1831
21. Stonesifer E, Fitzpatrick LR, Small J et al (2013) The synthetic triterpenoid (CDDO-IM) inhibits STAT3, as well as IL-17, and improves DSS-induced colitis. Gastroenterology p S807
22. Sutton C, Brereton C, Keogh B et al (2006) A crucial role for interleukin (IL)-1 in the induction of IL-17 producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 203:1685–1691
23. Sutton CE, Lalor SJ, Sweeney CM et al (2009) Interleukin-1 and IL-23 induce innate IL-17 production from γδ T cells amplifying TH17 responses and autoimmunity. Immunity 31:331–341
24. Wang Z, Bhattacharya N, Weaver M et al (2001) Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci 2:167–179
25. Yates MS, Kwak MK, Egner PA et al (2006) Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano3, 12-dioxooleana-1,9 (11)-dien-28-oyl-dien-28-oyl] imidazole. Cancer Res 66:2488–2494
26. Yore MM, Liby KT, Honda T et al (2006) The synthetic triterpenoid 1-[2-cyano3, 12-dioxooleana-1,9 (11)-dien-28-oyl-dien-28-oyl] imidazole blocks nuclear factor-κB activation through direct inhibition of IκB kinase β. Mol Cancer Ther 5:3232–3239